Tumor stroma is the supportive tissue surrounding and intermixed with cancer cells, made up of fibroblasts, immune cells, blood vessels, nerves, and a dense mesh of structural proteins collectively called the extracellular matrix. Far from being passive scaffolding, this stroma actively shapes how tumors grow, spread, resist treatment, and evade the immune system. A useful way to think about it: if the cancer cells are the seeds, the stroma is the soil, and the soil matters at least as much as the seeds. Research over the past two decades has fundamentally shifted oncology’s focus from cancer cells alone to the entire ecosystem they inhabit.
A Wound That Never Heals
One of the most clarifying descriptions of tumor stroma comes from an old but enduring analogy: a tumor behaves like a wound that does not heal. Normal wound healing involves recruiting fibroblasts to lay down new structural proteins, pulling in immune cells to fight infection, and sprouting new blood vessels to restore blood supply. Tumors co-opt every one of these processes. They recruit and activate fibroblasts, deposit extracellular matrix components, attract immune cells, stimulate new blood vessel growth, and even reprogram nearby cell types to take on new identities.1PubMed Central. The evolving relationship of wound healing and tumor stroma The key difference is that a wound eventually resolves. The stroma in a healing wound is spatially and temporally self-limited: it builds up, does its job, and then quiets down. In cancer, this remodeling process runs indefinitely, driving uncontrolled cell proliferation, tissue invasion, and resistance to therapy.2PubMed. Stroma in normal and cancer wound healing The edges of a tumor are constantly expanding, so the stromal “repair program” never receives the signal to stop.
The Major Players in Tumor Stroma
Tumor stroma is not one cell type. It is a collection of cell populations, each with distinct roles in supporting or sometimes restraining cancer progression. Understanding these players helps explain why stroma-targeted therapies are so complicated.
Cancer-Associated Fibroblasts
Fibroblasts are the workhorses of connective tissue, and in cancer they become something more sinister. Cancer-associated fibroblasts, or CAFs, are among the most abundant stromal cells in many solid tumors. They come from diverse origins: some are reprogrammed normal tissue fibroblasts, others derive from bone marrow cells or even from cancer cells themselves that have changed identity. CAFs shape the tumor microenvironment through a remarkable range of activities, including secreting growth factors, remodeling the matrix, and suppressing immune responses.3PubMed Central. Cancer-Associated Fibroblasts: Origin, Classification, Tumorigenicity, and Targeting for Cancer Therapy One well-studied mechanism involves the signaling molecule TGF-β1, which fibroblasts both produce and respond to. In bladder cancer, for example, stromal fibroblast-derived TGF-β1 promotes cancer cell migration and invasion while simultaneously converting normal fibroblasts into CAFs, creating a self-amplifying loop.4PubMed Central. TGF-β1 dominates stromal fibroblast-mediated EMT via the FAP/VCAN axis in bladder cancer cells
Tumor-Associated Macrophages
Macrophages are immune cells that normally eat debris and pathogens. In the tumor stroma, however, they frequently shift toward a state that actually helps the cancer. These tumor-associated macrophages closely resemble the “M2” subtype, which promotes tissue repair and suppresses inflammation rather than attacking threats. Studies consistently find that when more of these macrophages accumulate inside tumors, clinical outcomes tend to be worse. Experimental models support the idea that they create a favorable environment for both tumor emergence and progression.5PubMed Central. The role of tumor-associated macrophages in tumor immune evasion Beyond macrophages, the stromal immune compartment also includes neutrophils, regulatory T cells, and myeloid-derived suppressor cells, all of which can be co-opted by tumors to dampen the immune response.6PubMed Central. The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
Blood Vessels and Hypoxia
Tumors stimulate the growth of new blood vessels to feed themselves, a process called angiogenesis. But these tumor blood vessels are structurally abnormal: leaky, disorganized, and poorly functional. Because they cannot deliver oxygen efficiently, large portions of the tumor remain oxygen-starved. That low-oxygen environment, or hypoxia, is not just an inconvenience for the cancer cell. It actually fuels further tumor progression, drives metastasis, and makes the tumor more resistant to both chemotherapy and radiation.7Oncogene. Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment It is a vicious cycle: abnormal vessels cause hypoxia, which stimulates even more abnormal vessel growth, which perpetuates the problem.
How a Stiff Matrix Helps Cancer Spread
The extracellular matrix in and around a tumor is not just a passive meshwork. It is physically different from normal tissue. Cancerous tissue can be dramatically stiffer than its healthy counterpart, with stiffness values ranging roughly from 500 Pa in soft normal tissue to around 48,000 Pa in stiff tumor tissue.8PubMed Central. Extracellular Matrix Cues Regulate Mechanosensing and Mechanotransduction of Cancer Cells You can sometimes feel this difference yourself: a breast lump detected during a self-exam is often stiffer than the surrounding tissue precisely because of this dense, remodeled stroma.
That stiffness is not just a side effect. It actively promotes cancer progression by triggering mechanical sensors on cancer cells, which translate the physical force into chemical signals that encourage migration and invasion.9PubMed Central. Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer Recent research has identified specific proteins like polycystin-1 that act as mechanosensors on tumor cells. When these sensors detect stiff collagen-rich matrix, they activate signaling cascades that enhance cell motility and promote metastasis. Certain mutations in polycystin-1 have been linked to lymphatic and distant metastasis in breast cancer because they amplify this mechanical signaling even further.10PubMed Central. Polycystin-1 Mutant Alters Mechanotransduction in Response to Collagen and Extracellular Matrix Stiffness via Daam1-Dependent Microfilament Remodeling
Stroma Prepares Distant Sites for Metastasis
One of the more unsettling discoveries in cancer biology is that tumors can alter distant organs before any cancer cell actually arrives there. Primary tumors secrete factors into the bloodstream that cause microenvironmental changes in places like the liver, lungs, or bones, creating what researchers call a pre-metastatic niche.11PubMed Central. The metastatic niche and stromal progression The stromal cells at these distant sites are not bystanders. Fibroblasts in the pre-metastatic niche produce inflammatory molecules and growth factors, lay down fibronectin, and secrete enzymes that break down the normal matrix to make room for arriving cancer cells. Endothelial cells at these sites release signals that recruit immune cells, which in turn further remodel the tissue. In the liver specifically, specialized stromal cells called hepatic stellate cells can organize and accelerate metastasis by depositing matrix, boosting blood vessel growth factors, and drawing in macrophages.12Cancer Cell. Tumor Stroma and Pre-metastatic Niche in Cancer
This means the stroma’s influence extends well beyond the primary tumor. By the time cancer cells break off and enter the bloodstream, the soil at their destination may already be prepared for their arrival.
Why Drugs Struggle to Reach Tumor Cells
Tumor stroma creates a formidable physical barrier against drug delivery. The dense extracellular matrix deposited by activated fibroblasts increases the structural density of the tissue, while the leaky, dysfunctional blood vessels lead to elevated interstitial fluid pressure inside the tumor. Together, these factors mean that drugs entering the tumor vasculature face enormous resistance trying to penetrate into the tissue where the cancer cells actually live.13PubMed Central. Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid High interstitial fluid pressure is widely recognized as a key barrier across solid cancers in general, not just specific tumor types.14PubMed Central. Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure
The stiffened matrix compounds this problem. It does not just block drugs physically; it also activates receptors on cancer cells that can promote survival and resistance, meaning the stroma simultaneously prevents drugs from arriving and helps cancer cells survive whatever drug does get through.9PubMed Central. Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer This is a major reason why pancreatic cancer, for example, which has an extremely dense stroma, is so notoriously difficult to treat with conventional chemotherapy.
The Stroma as a Prognostic Marker
Because stroma plays such an active role in cancer progression, researchers have investigated whether simply measuring how much stroma a tumor contains could predict patient outcomes. The answer, across multiple cancer types, is yes. A systematic review covering over 4,200 patients with solid tumors found that tumors with a high proportion of stroma relative to cancer cells were associated with worse overall survival and worse disease-free survival.15PubMed Central. Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis This metric, called the tumor-stroma ratio, can be assessed from standard tissue samples that pathologists already examine, making it relatively low-cost to implement.
The prognostic value appears especially strong in certain subtypes. In early breast cancer, stroma-rich tumors were independently linked to shorter relapse-free periods and worse survival. Among triple-negative breast cancer patients specifically, those with stroma-rich tumors had roughly three times the risk of relapse compared to those with stroma-poor tumors, and five-year relapse-free rates were about 56% versus 81%.16PubMed. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients Similar findings have been reported in squamous cell lung cancer and other solid tumors.17PubMed. The prognostic value of the tumor-stroma ratio in squamous cell lung cancer, a cohort study
The Pancreatic Cancer Paradox
Given everything above, it might seem logical that destroying the tumor stroma would be a straightforward therapeutic strategy. Pancreatic cancer taught the field otherwise. Pancreatic tumors are famous for their extreme stromal density, and early thinking assumed that eliminating that stroma would expose the cancer cells to immune attack and drug delivery. But when researchers actually depleted the fibroblasts in mouse models of pancreatic cancer, the tumors became more invasive, less differentiated, and more necrotic. Survival was significantly reduced, not improved, in both early and late depletion settings.18Cancer Cell. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
This result sent shockwaves through the field. The stroma was not just helping the cancer; it was also physically restraining it to some degree, acting as a barrier to metastatic spread. Depleting the stroma removed that restraint and simultaneously triggered immunosuppression. The takeaway is that stroma-targeting therapy is a double-edged sword: the same stroma that feeds and protects the tumor can also inhibit its metastasis and malignancy.19PubMed. Reflections on depletion of tumor stroma in pancreatic cancer This paradox has pushed the field toward more nuanced strategies that aim to reprogram the stroma rather than obliterate it.
Therapeutic Strategies Targeting the Stroma
Because indiscriminately destroying stroma can backfire, current research focuses on selectively targeting the most harmful stromal components while leaving protective functions intact. A major target is fibroblast activation protein (FAP), a surface protein found on many cancer-associated fibroblasts but largely absent from normal adult tissues. Several approaches are being explored:
- Immunocytokines: Simlukafusp alfa binds FAP on tumor-associated fibroblasts and enhances immune cell activity, and is currently in Phase II trials for advanced melanoma, kidney cancer, and pancreatic cancer in combination with immune checkpoint therapy.
- Small-molecule FAP inhibitors: Talabostat, a FAP inhibitor, is under investigation alongside anti-PD-1 therapy in advanced solid tumors, aiming to reduce the immune suppression that CAFs impose on the tumor environment.20Oncology Reviews. Fibroblast activation protein and the tumour microenvironment: challenges and therapeutic opportunities
- Engineered cell therapies: MiNK-215 is an experimental therapy in which immune cells are engineered to carry a FAP-targeting receptor and secrete an immune-boosting signal. In mouse models of lung cancer, it depleted FAP-positive fibroblasts, increased immune cell infiltration, and produced durable anti-tumor responses without off-target toxicity. Early results in human organoid models of treatment-resistant colorectal cancer liver metastases have also been encouraging.21PubMed. The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
- Oncolytic virus combinations: Researchers have engineered cancer-killing viruses to secrete molecules that redirect T cells against FAP-positive fibroblasts, combining direct viral destruction of cancer cells with immune targeting of the supportive stroma.22PubMed Central. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager
The central challenge with all of these approaches is that CAFs are not one uniform population. Some promote tumor growth, others restrain it, and still others appear to switch between these roles depending on context. Selective inhibition of the harmful subsets while preserving anti-tumor fibroblast functions remains an ongoing area of research.20Oncology Reviews. Fibroblast activation protein and the tumour microenvironment: challenges and therapeutic opportunities
Metabolic Parasitism Between Stroma and Cancer
The relationship between tumor cells and their stroma extends into metabolism in ways that surprised researchers when first described. In what has been called the “Reverse Warburg Effect,” aggressive cancer cells use oxidative stress as a weapon to extract nutrients from surrounding stromal fibroblasts. The oxidative stress forces fibroblasts to destroy their own mitochondria and switch to a less efficient form of energy production, churning out energy-rich molecules like lactate and ketones. Cancer cells then absorb these nutrients to fuel their own growth. In this model, stromal cells are essentially forced into a catabolic state, breaking themselves down, to sustain the anabolic growth of the tumor.23PubMed Central. Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment The comparison to parasitism is apt: the cancer cells exploit neighboring cells as nutrient sources, draining them to feed their own expansion.
Nerves in the Tumor Stroma
A more recently appreciated stromal component is the nervous system. Tumors can recruit peripheral nerves into the tumor microenvironment, a process called tumor innervation. This is associated with a more aggressive tumor profile and worse prognosis across multiple cancer types. Locally delivered neurotransmitters from these nerves have been implicated in driving cancer cell proliferation, invasion, metastasis, and immune evasion.24PubMed Central. Tumor innervation: peripheral nerves take control of the tumor microenvironment This is a frontier area with considerable clinical interest. Some researchers are investigating whether drugs that block nerve signaling, including commonly used beta-blockers, could reduce the pro-tumor effects of innervation, though this work is still largely in early stages.
Aging Stroma and Cancer Risk
The connection between stroma and cancer also helps explain one of the most basic epidemiological facts about the disease: cancer becomes much more common as people age. The conventional explanation focuses on mutations accumulating over a lifetime, but the stromal perspective adds a complementary piece. As tissues age, fibroblasts and epithelial cells undergo cellular senescence, a state where they stop dividing but do not die. These senescent cells secrete a cocktail of factors that can disrupt normal tissue architecture and stimulate nearby cells to proliferate. The resulting tissue environment becomes increasingly hospitable to cancer. Senescent stromal fibroblasts may be especially effective at creating this pro-cancer milieu, synergizing with accumulated mutations to drive the steep rise in cancer incidence with age.25PubMed. Cancer and aging: a model for the cancer promoting effects of the aging stroma In other words, it is not just that old cells carry more mutations. The soil itself becomes more fertile for cancer over time.
Building Better Lab Models
One practical consequence of recognizing stroma’s importance is that cancer research models need to include it. Traditional lab experiments that grow cancer cells in flat plastic dishes strip away the stromal context entirely, which means they miss many of the interactions that drive real tumor behavior. Clinically relevant three-dimensional models that recapitulate the complex interplay between tumor and stromal cells are increasingly seen as necessary for both understanding cancer biology and testing new therapies.26Trends in Cancer. What Is Tumor Stroma and Why Is It Important in Cancer?
Recent bioengineering work has demonstrated this concretely. When researchers assembled three-dimensional prostate cancer spheroids with and without stromal elements, the inclusion of stromal cells proved essential for generating robust, reproducible tumor models with consistent morphology and size. The metabolic profiles of these stroma-containing models differed substantially from those of cancer-cell-only models, and drug responses changed as well.27PubMed. Bioengineered Tumor-Stroma Prostate Cancer In Vitro Models for Screening Therapeutics The implication for drug development is significant: a compound that kills cancer cells in a dish may fail in a patient because the stroma in the real tumor alters the cancer cell’s behavior, metabolism, and drug sensitivity. Testing against stroma-inclusive models catches some of these failures earlier, potentially saving years of development time and sparing patients from ineffective treatments in clinical trials.
An Evolutionary Perspective on Stromal Hijacking
The stromal machinery that tumors exploit is not something cancer invented. It is deeply embedded in animal biology. FAP, the fibroblast activation protein that cancer-associated fibroblasts express and that researchers are now targeting therapeutically, is conserved throughout chordate evolution, with related versions found in species as distant as the African clawed frog. Its expression in these organisms correlates with tissue remodeling events like wound healing and development.28Journal of Biological Chemistry. Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts Cancer cells are not building new biology; they are hijacking ancient tissue-repair programs that evolved long before tumors became a significant cause of death. The very effectiveness of these programs at rebuilding wounded tissue is what makes them so dangerous when a tumor commandeers them without an off switch.